Peptide Comparison
Mazdutide vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Orforglipron has stronger documented evidence (FDA-Approved) than Mazdutide (Phase 3 (China)) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. Mazdutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: gi effects. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Mazdutide | Orforglipron | |
|---|---|---|
| Class | GLP-1/glucagon dual agonist | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Oxyntomodulin analog; activates GLP-1 and glucagon receptors | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection | Oral |
| Half-life | Long-acting weekly | ~29-49 hrs |
| Dosage (research) | 3-9 mg SC weekly | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | Phase 3 (China) | FDA-Approved |
| Research depth | 126 indexed | 197 indexed |
| Availability | Investigational | Prescription |
| Reported risks | GI effects; no Western approval | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Mazdutide or Orforglipron?
Orforglipron has stronger documented evidence (FDA-Approved) than Mazdutide (Phase 3 (China)) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. Mazdutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Mazdutide and Orforglipron?
Mazdutide is classed as GLP-1/glucagon dual agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Mazdutide, Oxyntomodulin analog; activates GLP-1 and glucagon receptors; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Mazdutide, Long-acting weekly; Orforglipron, ~29-49 hrs. Routes in published studies: Mazdutide, SC injection; Orforglipron, Oral.
Which has stronger evidence, Mazdutide or Orforglipron?
Orforglipron has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Mazdutide is graded Phase 3 (China), with 23 cited sources on its reference page and 126 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.
Which is more accessible, Mazdutide or Orforglipron?
Orforglipron is FDA-approved and Mazdutide is not. Catalog status: Mazdutide, Investigational; Orforglipron, Prescription.
Are Mazdutide and Orforglipron ever combined?
Mazdutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…